Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) CFO Patrik Jeanmonod sold 3,500 shares of the company's stock in a transaction on Tuesday, January 24th. The stock was sold at an average price of $11.05, for a total value of $38,675.00. Following the completion of the sale, the chief financial officer now directly owns 76,132 shares in the company, valued at $841,258.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Patrik Jeanmonod also recently made the following trade(s):
Get Cytek Biosciences alerts:- On Tuesday, December 27th, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The stock was sold at an average price of $9.77, for a total transaction of $34,195.00.
- On Friday, November 25th, Patrik Jeanmonod sold 3,500 shares of Cytek Biosciences stock. The shares were sold at an average price of $14.30, for a total transaction of $50,050.00.
Cytek Biosciences Stock Performance
CTKB stock traded up $0.29 during trading on Wednesday, hitting $11.53. 645,055 shares of the stock traded hands, compared to its average volume of 781,979. Cytek Biosciences, Inc. has a 1 year low of $7.38 and a 1 year high of $16.05. The firm's 50 day moving average is $11.62 and its two-hundred day moving average is $12.99.
Cytek Biosciences (NASDAQ:CTKB – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.01). The firm had revenue of $40.48 million for the quarter, compared to analysts' expectations of $43.36 million. Cytek Biosciences had a negative net margin of 0.47% and a positive return on equity of 0.94%. Sell-side analysts expect that Cytek Biosciences, Inc. will post 0.04 EPS for the current fiscal year.Wall Street Analyst Weigh In
Separately, Piper Sandler raised their price objective on Cytek Biosciences from $16.00 to $18.00 in a research report on Monday, November 14th.
Institutional Investors Weigh In On Cytek Biosciences
Several large investors have recently bought and sold shares of CTKB. Parkwood LLC raised its stake in Cytek Biosciences by 44.3% during the 2nd quarter. Parkwood LLC now owns 42,292 shares of the company's stock valued at $42,000 after buying an additional 12,981 shares during the last quarter. Pura Vida Investments LLC lifted its holdings in Cytek Biosciences by 12.4% in the second quarter. Pura Vida Investments LLC now owns 477,164 shares of the company's stock valued at $5,120,000 after acquiring an additional 52,587 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Cytek Biosciences in the second quarter worth about $175,000. Principal Financial Group Inc. increased its position in shares of Cytek Biosciences by 519.3% during the 2nd quarter. Principal Financial Group Inc. now owns 98,400 shares of the company's stock valued at $1,056,000 after purchasing an additional 82,510 shares during the last quarter. Finally, Swiss National Bank bought a new position in shares of Cytek Biosciences in the 2nd quarter worth approximately $1,696,000. 49.48% of the stock is currently owned by institutional investors.
Cytek Biosciences Company Profile
(Get Rating)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Featured Stories
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.